The analysis demonstrates clinical remission in 52.5% (n=114) of 217 moderate to severe ulcerative colitis (UC) patients (intent-to-treat population, ITT) after two years (96 weeks) of once-daily oral
EQS-News: ABIVAX / Key word: Study results
Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis
17.04.2023 / 18:00. | April 17, 2023
/PRNewswire/ CalciMedica Inc. ("CalciMedica" or the "Company), a clinical-stage biotechnology platform company targeting calcium release-activated calcium.